Epigenetics in inflammatory bowel disease (IBD)
- Prosjektnummer
- SFP1209-14
- Ansvarlig person
- Ruth H. Paulssen
- Institusjon
- UiT Norges arktiske universitet
- Prosjektkategori
- ph.d.-stipend
- Helsekategori
- Inflammatory and immune system
- Forskningsaktivitet
- 4. Detection and Diagnosis
The Norwegian Hospital Procurement Trust, Division drug procurements (LIS) has on behalf of the Regional Health Authorities established an advisory board of biological agents (anti-TNF group) consisting of specialists and participants from user organization (LMF, https://www.lmfnorge.no/) where our collaborator Jon Florholmen is a board member. A more direct contact towards the patient organization and its members has been ongoing through direct patient contact and meetings in the three health regions involved in the study. Through these communication routes the users have impact on decision on who should be offered the high cost and highly effective biological treatment (anti-TNF). Personalized treatment options, like choice of treatment, timing of escalation/de-escalation of treatment, will be highly beneficial for UC patients thereby improving their quality of life.
LIS-sykehusapotekenes innkjøpsordning har på vegne av de regionale helseforetakene etablert et rådgivende utvalg for biologiske midler (anti-TNF-gruppen) bestående av spesialister og deltakere fra brukerorganisasjoner (Landsforeningen mot fordøyelsessykdommer) hvor vår samarbeidspartner Jon Florholmen er styremedlem. En mer direkte kontakt mot brukerorganisasjonen og dens medlemmer har pågått gjennom direkte pasientkontakt og møter i de tre helseregionene som er involvert i ASIB-studien. Gjennom disse kommunikasjonsveiene har brukerne innflytelse på beslutningen om hvem som skal tilbys den høye kostnaden og høyeffektiv biologisk behandling (anti-TNF), og hvem som vil ha nytte av å stoppe den biologiske behandlingen.
Det har ikke vært noe brukermedvirkning i dette prosjekt i 2020 på grunn av Covid-19 pandemien.
The Norwegian Drug Procurement Corporation (LIS- sykehusapotekenes innkjøpsordning) has on behalf of the Regional Health Authorities established an advisory board of biological agents (anti-TNF group) consisting of specialists and participants from users organizations (Landsforeningen mot fordøyelsessykdommer) where our collaborator Jon Florholmen is a board member. A more direct contact towards the users organization and its members has been ongoing through direct patient contact and meetings in the three Health regions involved in the study. Through these communication routes the users have impact on decision on who should be offered the high cost and highly effective biological treatment (anti-TNF), and who would have benefit on stop the biologic therapy. Personalized treatment options, like choice of treatment, timing of escalation/de-escalation of treatment, will be highly beneficial for UC patients thereby improving their quality of life.
The Norwegian Drug Procurement Corporation (LIS- sykehusapotekenes innkjøpsordning) has on behalf of the Regional Health Authorities established an advisory board of biological agents (anti-TNF group) consisting of specialists and participants from users organizations (Landsforeningen mot fordøyelsessykdommer) where our collaborator Jon Florholmen is a board member. A more direct contact towards the users organization and its members has been ongoing through direct patient contact and meetings in the three Health regions involved in the study. Through these communication routes the users have impact on decision on who should be offered the high cost and highly effective biological treatment (anti-TNF), and who would have benefit on stop the biologic therapy. Personalized treatment options, like choice of treatment, timing of escalation/de-escalation of treatment, will be highly beneficial for UC patients thereby improving their quality of life.
DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis.
PLoS One 2021;16(4):e0248905. Epub 2021 apr 1
PMID: 33793617 - Inngår i doktorgradsavhandlingen
Transcriptional Signatures That Define Ulcerative Colitis in Remission.
Inflamm Bowel Dis 2021 01 01;27(1):94-105.
PMID: 32322884
Genome-wide DNA Methylation in Treatment-naïve Ulcerative Colitis.
J Crohns Colitis 2018 Nov 15;12(11):1338-1347.
PMID: 30137272 - Inngår i doktorgradsavhandlingen
Transcriptomic Landscape of Treatment-Naïve Ulcerative Colitis.
J Crohns Colitis 2018 Feb 28;12(3):327-336.
PMID: 29040430 - Inngår i doktorgradsavhandlingen
Epigenetics in Inflammatory Bowel Disease
- Disputert:
- april 2022
- Hovedveileder:
- Ruth H. Paulssen
- Inga Viktoria Hensel Prosjektdeltaker
- Ruth H Paulssen Prosjektleder
- Jon Florholmen Forskningsgruppeleder
- Christopher Graham Fenton Prosjektdeltaker
- Endre Anderssen Prosjektdeltaker
- Hagar Mohamed Taman Doktorgradsstipendiat
- Rasmus Goll Prosjektdeltaker
- Renathe Rismo Prosjektdeltaker
- Amir Rad Doktorgradsstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport, Helse Nord